Why the study?
Although cardiac fibrosis is common and widespread, effective drugs to provide adequate clinical intervention remain lacking.
This review provides a comprehensive overview of compounds with anti-cardiac fibrosis activity, serving as a reference for future drug design and repurposing.
Review classifies candidate antifibrotic compounds; leaves open clinical translation pending trials.
Coronary heart disease, hypertension, myocarditis, and valvular disease cause myocardial fibrosis, leading to heart enlargement, heart failure, heart rate failure, arrhythmia, and premature ventricular beat, even defibrillation can increase the risk of sudden death. Although cardiac fibrosis is common and widespread, there are still no effective drugs to provide adequate clinical intervention for cardiac fibrosis. In this review article, we classify the compounds for treating cardiac fibrosis into natural products, synthetic compounds, and patent drugs according to their sources. Additionally, the structures, activities and signaling pathways of these compounds are discussed. This review provides insight and could provide a reference for the design of new anti-cardiac fibrosis compounds and the new use of older drugs.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: